Combination diuretic therapies in heart failure: Insights from GUIDE-IT

IF 1.8 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS American heart journal plus : cardiology research and practice Pub Date : 2024-07-30 DOI:10.1016/j.ahjo.2024.100436
Jeffery Budweg , Mustafa M. Ahmed , Juan R. Vilaro , Mohammad A. Al-Ani , Juan M. Aranda Jr , Yi Guo , Ang Li , Sandip Patel , Alex M. Parker
{"title":"Combination diuretic therapies in heart failure: Insights from GUIDE-IT","authors":"Jeffery Budweg ,&nbsp;Mustafa M. Ahmed ,&nbsp;Juan R. Vilaro ,&nbsp;Mohammad A. Al-Ani ,&nbsp;Juan M. Aranda Jr ,&nbsp;Yi Guo ,&nbsp;Ang Li ,&nbsp;Sandip Patel ,&nbsp;Alex M. Parker","doi":"10.1016/j.ahjo.2024.100436","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Diuretics are the mainstay of maintaining and restoring euvolemia in the management of heart failure. Loop diuretics are often preferred, however, combination diuretic therapy (CDT) with a thiazide diuretic is often used to overcome diuretic resistance and increase diuretic effect. We performed an analysis of the GUIDE-IT study to assess all-cause mortality and time to first hospitalizations in patients necessitating CDT.</p></div><div><h3>Methods</h3><p>Patients from the GUIDE-IT dataset were stratified by their requirement for CDT with a thiazide to achieve euvolemia. A total of 894 patients were analyzed, 733 of which were treated with loop diuretics alone vs 161 used either chlorothiazide or metolazone in addition to loop diuretics. Kaplan-Meir curves were derived with log-rank <em>p</em>-values to evaluate for differences between the groups.</p></div><div><h3>Results</h3><p>There was no significant difference in all-cause mortality regardless of CDT utilization status (mean survival of 612.704 days vs 603.326 days, <em>p</em> = 0.083). On subgroup analysis, there was no significant difference in all-cause mortality amongst those using loop diuretics compared to CDT in the BNP-guided therapy group, (mean survival time 576.385 days vs 620.585 days, <em>p</em> = 0.0523), nor the control group (614.1 days vs 588.9 days; <em>p</em> = 0.5728). Time to first hospitalization was reduced in all using CDT compared to loop diuretics alone (280.5 days vs 407.2 days, <em>p</em> &lt; 0.0001). On subgroup analysis, both the BNP-guided group as well as the control group had reduced time to first hospitalization in the CDT group compared to those who did not require CDT (BNP group: 287.503 days vs 402.475 days, <em>p</em> ≤0.0001; control group 248.698 days vs 399.035 days, <em>p</em> = 0.0009).</p></div><div><h3>Conclusion</h3><p>Use of CDT is associated with earlier time to hospitalization, though no association was identified with increased all-cause mortality. Further prospective studies are likely needed to determine the true risk and benefits of combination diuretic therapy.</p></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"45 ","pages":"Article 100436"},"PeriodicalIF":1.8000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266660222400079X/pdfft?md5=286071745bf1d2e77b4c6dfd626c8222&pid=1-s2.0-S266660222400079X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American heart journal plus : cardiology research and practice","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266660222400079X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Diuretics are the mainstay of maintaining and restoring euvolemia in the management of heart failure. Loop diuretics are often preferred, however, combination diuretic therapy (CDT) with a thiazide diuretic is often used to overcome diuretic resistance and increase diuretic effect. We performed an analysis of the GUIDE-IT study to assess all-cause mortality and time to first hospitalizations in patients necessitating CDT.

Methods

Patients from the GUIDE-IT dataset were stratified by their requirement for CDT with a thiazide to achieve euvolemia. A total of 894 patients were analyzed, 733 of which were treated with loop diuretics alone vs 161 used either chlorothiazide or metolazone in addition to loop diuretics. Kaplan-Meir curves were derived with log-rank p-values to evaluate for differences between the groups.

Results

There was no significant difference in all-cause mortality regardless of CDT utilization status (mean survival of 612.704 days vs 603.326 days, p = 0.083). On subgroup analysis, there was no significant difference in all-cause mortality amongst those using loop diuretics compared to CDT in the BNP-guided therapy group, (mean survival time 576.385 days vs 620.585 days, p = 0.0523), nor the control group (614.1 days vs 588.9 days; p = 0.5728). Time to first hospitalization was reduced in all using CDT compared to loop diuretics alone (280.5 days vs 407.2 days, p < 0.0001). On subgroup analysis, both the BNP-guided group as well as the control group had reduced time to first hospitalization in the CDT group compared to those who did not require CDT (BNP group: 287.503 days vs 402.475 days, p ≤0.0001; control group 248.698 days vs 399.035 days, p = 0.0009).

Conclusion

Use of CDT is associated with earlier time to hospitalization, though no association was identified with increased all-cause mortality. Further prospective studies are likely needed to determine the true risk and benefits of combination diuretic therapy.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
心力衰竭的联合利尿疗法:来自 GUIDE-IT 的启示
导言:在治疗心力衰竭的过程中,利尿剂是维持和恢复血容量的主要药物。襻利尿剂通常是首选药物,但为了克服利尿剂耐药性并提高利尿效果,通常会使用噻嗪类利尿剂联合利尿疗法(CDT)。我们对 GUIDE-IT 研究进行了分析,以评估需要 CDT 患者的全因死亡率和首次住院时间。共对 894 例患者进行了分析,其中 733 例患者仅使用襻利尿剂,161 例患者在使用襻利尿剂的同时还使用了氯噻嗪或美托拉宗。结果无论使用 CDT 与否,全因死亡率均无显著差异(平均生存期为 612.704 天 vs 603.326 天,p = 0.083)。在亚组分析中,使用襻利尿剂的患者与使用 CDT 的 BNP 指导治疗组(平均存活时间为 576.385 天 vs 620.585 天,p = 0.0523)和对照组(614.1 天 vs 588.9 天;p = 0.5728)相比,全因死亡率无明显差异。与单独使用襻利尿剂相比,所有使用 CDT 的患者首次住院时间都缩短了(280.5 天 vs 407.2 天,p < 0.0001)。亚组分析显示,与不需要 CDT 的患者相比,BNP 引导组和对照组的 CDT 患者首次住院时间均有所缩短(BNP 组:287.503 天 vs 402.475 天,p ≤0.0001;对照组 248.698 天 vs 399.035 天,p = 0.0009)。要确定联合利尿疗法的真正风险和益处,可能还需要进一步的前瞻性研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.60
自引率
0.00%
发文量
0
审稿时长
59 days
期刊最新文献
SGLT2 inhibitor therapy and clinical outcomes in HIV-related cardiomyopathy Initiation, titration, and safety of vericiguat for treatment of heart failure in United States clinical practice Three different indications for left ventricular unloading in one patient with severe heart failure Symptom phenotypes and coronary microvascular function in non-obstructive coronary artery disease: Insights beyond epicardial ischemia A risk model to predict atrial fibrillation in diabetes using machine learning: The ACCORD study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1